

AI
cancel.

26, 1997, and a continuation-in-part of U.S. Patent Application Serial No. 08/660,542, filed June 7, 1996 (now U.S. Patent No. 5,932,703, issued August 3, 1999), and a continuation-in-part of U.S. Patent Application Serial No. 08/558,658, filed November 16, 1995 (now abandoned), and a continuation-in-part of pending U.S. Patent Application Serial No. 08/479,620, filed June 7, 1995. All of these priority applications are incorporated by reference in their entirety.--

In the Claims:

Please cancel claims ~~15~~-25.

Please amend claims ~~4~~ 6, ~~30~~, and ~~31~~ as shown below:

4. (Amended) A purified polypeptide according to claim 1 [any of claims 1-3], selected from the group consisting of:

(a) a polypeptide comprising a sequence of amino acids identified by positions 1 to 68 of SEQ ID NO: 36;

A2
(b) a polypeptide comprising a sequence of amino acids identified by positions 1 to 69 of SEQ ID NO: 38; and

(c) a polypeptide comprising a sequence of amino acids identified by positions 1 to 69 of SEQ ID NO: 46.

5. (Amended) A pharmaceutical composition comprising a purified polypeptide according to claim 1 [any one of claims 1-4] in a pharmaceutically acceptable carrier.

6. (Amended) A purified polynucleotide comprising a nucleotide sequence that encodes a polypeptide according to claim 1 [any one of claims 1-4].